Is Buying Adverum Biotechnologies Inc (NASDAQ:ADVM) Here Good Idea?

June 17, 2018 - By Kurt Siggers

The stock of Adverum Biotechnologies Inc (NASDAQ:ADVM) registered a decrease of 9.43% in short interest. ADVM’s total short interest was 2.11M shares in June as published by FINRA. Its down 9.43% from 2.33M shares, reported previously. With 450,800 shares average volume, it will take short sellers 5 days to cover their ADVM’s short positions. The short interest to Adverum Biotechnologies Inc’s float is 8.65%.

It closed at $5.55 lastly. It is down 132.08% since June 17, 2017 and is uptrending. It has outperformed by 119.51% the S&P500.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has market cap of $345.61 million. The firm has a pipeline that includes product candidates to treat wet age-related macular degeneration , alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. It currently has negative earnings. The Company’s lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT.

More recent Adverum Biotechnologies, Inc. (NASDAQ:ADVM) news were published by: Nasdaq.com which released: “Adverum Biotechnologies to Present at the 2018 Jefferies Global Healthcare Conference” on June 04, 2018. Also Nasdaq.com published the news titled: “Analysis: Positioning to Benefit within Kinross Gold, New York Mortgage Trust, POSCO, NXP Semiconductors NV …” on June 04, 2018. Seekingalpha.com‘s news article titled: “Adverum: Assessing The Strong Prospects Of A Gene Therapy Innovator” with publication date: May 23, 2018 was also an interesting one.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.